EXEL : Summary for Exelixis, Inc. - Yahoo Finance

U.S. Markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.40+0.16 (+0.72%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close22.24
Bid21.30 x 1000
Ask25.00 x 200
Day's Range22.10 - 22.51
52 Week Range4.25 - 23.49
Avg. Volume4,484,814
Market Cap6.55B
PE Ratio (TTM)-80.00
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 5 Things Bristol-Myers Squibb's Management Wants You to Know
    Motley Fool6 hours ago

    5 Things Bristol-Myers Squibb's Management Wants You to Know

    Bristol-Myers Squibb knocked it out of the park with its Q1 earnings.

  • Market Realistyesterday

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

  • Capital Cube2 days ago

    Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : April 27, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Exelixis, Inc. a score of 31. Our analysis is based on comparing Exelixis, Inc. with the following peers – Sanofi Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Johnson & Johnson, ArQule, Inc., Pfizer Inc., AVEO Pharmaceuticals, Inc. and Curis, ... Read more (Read more...)